Lymphatic Drainage From the Brain Could Hold the Key to Multiple Sclerosis Treatment

Human brain's lymphatic vessels have been found to signal immune cells to enter the brain, finds a new study. By blocking this passage, multiple Sclerosis can be treated.

Lymphatic vessels have been found to carry a mysterious message from the brain to the immune cells to cause Multiple Sclerosis finds a new study. The findings of this study are published in the Nature Neuroscience journal.

The vessels appear to carry previously unknown messages from the brain to the immune system that ultimately trigger the disease symptoms. Blocking those messages may offer doctors a new way to treat a potentially devastating condition that affects more than 2 million people.

Roadmap for Repairing the Damage of Multiple Sclerosis
Research provides new understanding about how drugs can repair damaged brain cells that cause disability in patients with multiple sclerosis.

‘It was also found that while blocking the vessels did benefit in the multiple sclerosis model, but the lab had also shown that the vessels' healthy function is vital to staving off Alzheimer's disease and preventing the cognitive decline that comes with age.’

The discovery comes from the lab of UVA researchers who identified the lymphatic vessels surrounding the brain, vessels that textbooks long insisted did not exist. In an exciting follow-up, the researchers have determined that the vessels play an important role in not only multiple sclerosis but, most likely, many other neuroinflammatory diseases and in dangerous brain infections.

"Our data suggests that there is a signal coming from the brain to the lymph nodes that tells immune cells to get back into the brain, causing the [multiple sclerosis] pathology," said researcher Antoine Louveau, PhD, of UVA’s Department of Neuroscience and its Center for Brain Immunology and Glia (BIG). "This is an important proof of principle that exploring the role of these vessels in different neurological disorders, including multiple sclerosis, is worth it."

Stopping Multiple Sclerosis

Fasting Can Improve Multiple Sclerosis Symptoms in Mice
Intermittent fasting can reduce multiple sclerosis (MS) symptoms. Fasting may also improve the immune system and gut bacteria that link to milder MS-like symptoms.

The researchers at UVA, led by Jonathan Kipnis, Ph.D., were able to impede the development of multiple sclerosis in mice by targeting the lymphatic vessels surrounding the brain. They used multiple strategies to block the lymphatics or destroy them with a precision laser. All led to the same outcome: a decrease in the number of destructive immune cells capable of causing paralysis.

"The idea was to prevent more widespread damage to the nervous system," said researcher Jasmin Herz. "If communication of brain inflammation through lymphatic vessels is the root cause of multiple sclerosis, therapies targeting these vessels could be clinically important."

Enzyme That Causes Cell Death in Multiple Sclerosis Identified
Cell death also called 'fiery death' of brain cells in multiple sclerosis has been linked to an enzyme called ‘gasdermin’ (GSDMD). This process of cell death in multiple sclerosis is also known as ‘pyroptosis’.

The message from the brain that appears to drive multiple sclerosis remains poorly understood. The researchers can tell the message is being sent, and they can tell what it is instructing the immune system to do, but they don’t yet know what mechanism the brain is using to send it. "I think the next step in this specific research is to identify what that signal is. Is it a cellular signal, is it a molecular signal?" Louveau said. "And then to try to target that signal specifically."

The researchers noted that removing the vessels did not stop multiple sclerosis entirely. That suggests there are likely other factors at play - and much more for scientists to explore.

Exposure to Paint and Varnish may Up Risk of Multiple Sclerosis
Exposure to paint, varnish and other solvents can put people at a 50 percent higher risk of developing multiple sclerosis (MS). The risk is even greater for people who have been smokers.

An Important Proof of Principle

UVA’s new research offers important insight into the function and role of the lymphatic vessels that connect the brain to the immune system. In most aspects, they work exactly as scientists would expect - just like other lymphatic vessels in the body.

"Meningeal lymphatic vessels are quite small compared to other lymphatics in the body, and we and others wondered if this might limit the amount and size of cargo they can pass through," Herz said. "During inflammation, they did not change in size or complexity much, but what was really exciting to discover [was that] they allowed whole immune cells to traffic through them, and we found the molecular cues for that."

But the lab’s recent research also highlights the complexity doctors face when trying to manipulate the vessels to benefit human health. For example, blocking the vessels had a benefit in the multiple sclerosis model, but the lab has also shown that the vessels’ healthy function is vital to staving off Alzheimer’s disease and preventing the cognitive decline that comes with age.

That means that it’s unlikely that stopping MS could be as simple as blocking the flow inside the vessels. It also suggests that there is probably no one treatment approach that will work for every neurological disorder. But the emerging importance of the vessels offers doctors an exciting new avenue for tackling neurological diseases.

"These findings on the role of brain-draining lymphatic vessels in MS, together with our recent work on their role in Alzheimer’s disease, demonstrate that the brain and the immune system are closely interacting. When these interactions go out of control, pathologies emerge," said Kipnis, chairman of UVA’s Department of Neuroscience and director of the BIG Center. "The idea that we could target major neurological disorders through therapeutic manipulation of peripheral structures, such as lymphatic vessels, is beyond exciting. Through our collaboration with PureTech Health, we hope to bring these laboratory findings to improve patients’ lives one day."

Kipnis recently signed a deal with biopharmaceutical company PureTech Health to explore the potential clinical applications of his discoveries.

Source-Eurekalert